发明授权
- 专利标题： Chromosome 17P-linked prostate cancer susceptibility gene
- 专利标题（中）： 染色体17P连接前列腺癌易感基因
-
申请号： US09434382申请日： 1999-11-05
-
公开(公告)号： US06844189B1公开(公告)日： 2005-01-18
- 发明人: Sean V. Tavtigian , David H.-F. Teng , Jacques Simard , Johanna M. Rommens , Lisa A. Cannon Albright , Susan L. Neuhausen
- 申请人： Sean V. Tavtigian , David H.-F. Teng , Jacques Simard , Johanna M. Rommens , Lisa A. Cannon Albright , Susan L. Neuhausen
- 申请人地址： US UT Salt Lake City US UT Salt Lake City CA Toronto
- 专利权人： Myriad Genetics, Inc.,University of Utah Research Foundation,Hospital for Sick Children
- 当前专利权人： Myriad Genetics, Inc.,University of Utah Research Foundation,Hospital for Sick Children
- 当前专利权人地址： US UT Salt Lake City US UT Salt Lake City CA Toronto
- 代理商 Jeffrey Ihnen; Herbert L. Ley, III; Jay Z. Zhang
- 主分类号： G01N33/50
- IPC分类号： G01N33/50 ; A61K31/713 ; A61K38/00 ; A61K39/395 ; A61K45/00 ; A61K48/00 ; A61P35/00 ; C07H21/04 ; C07K14/435 ; C07K14/47 ; C07K16/18 ; C07K16/30 ; C07K16/44 ; C12N1/15 ; C12N1/19 ; C12N1/21 ; C12N5/10 ; C12N9/64 ; C12N15/09 ; C12N15/12 ; C12P21/02 ; C12P21/04 ; C12Q1/68 ; G01N33/15 ; G01N33/53 ; G01N33/566 ; G01N33/577 ; G01N37/00 ; C12N5/16 ; C12N15/63
摘要：
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the HPC2 gene, (including gene therapy, protein replacement therapy, protein mimetics, and inhibitors). The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the HPC2 gene for mutations, which are useful for diagnosing the predisposition to prostate cancer.
信息查询
IPC分类:
